An overview of the regulatory framework for advanced therapies

By Regulatory Affairs Workgroup, SINDUSFARMA2023-04-06T07:57:00

Source: Adobe Stock

Advanced therapy medicinal products (ATMPs) have recently advanced in development and are subject to regulation in some markets. This article summarises the regulatory framework for ATMPs in some of the markets where these requirements are in place: Argentina, Brazil, Europe, and the US.

How to read this journal article

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

REGISTER FOR FREE

Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

Create your own library to save your favourite content.
Sign up for Regulatory Rapporteur email newsletters.

Create a free account

Members login

Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.

JOIN TOPRA

TOPRA membership

Become a TOPRA member and join our global community of regulatory affairs professionals.

Great savings on our events and training.
Be part of our dynamic international community.
Contribute to the profession.
Grow your skills and knowledge.
Take your career to the next level.

Become a member